top

Discover

 

Coronary

Absorb: A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

Short Description:This study is comparing the Abbott Vascular Absorb Bioresorbable Vascular Scaffold System (Absorb BVS) to Xience stents in treating narrowed coronary arteries. The Absorb BVS is a temporary device which functions like a drug-eluting stent, but is made out of a plastic scaffold (as opposed to metal). Over time, the scaffold will break down and be resorbed into the artery wall leaving behind no permanent implant. Absorb BVS is a combination of a scaffold, the drug everolimus, and a delivery system. The Absorb BVS and Xience stents all use the drug everolimus to prevent the heart artery from re-narrowing. Bioresorbable Platforms may just be the Fourth Revolution in Coronary Stenting. The potential advantages of this new technology are:
• Restoration of natural physiologic vasomotor function in some patients
• Enable vascular remodeling and tissue adaptation
• Elimination of chronic sources of vessel irritation and sources for chronic inflammation
• Potentially reduce the need for prolonged DAPT
• Potential reduction of incidence of stent thrombosis
• Possibly avoid current challenges with leaving a metal implant behind
• Non-invasive imaging with MSCT or MRA without ‘blooming artifact’

Please contact Kate Dalton, MS, RD, CCRC at keb2114@columbia.edu if you have questions or would like to refer a patient.

Principal Investigator: Jeffrey W. Moses, MD

https://clinicaltrials.gov/ct2/show/NCT01751906?term=absorb&rank=1

Sponsor: Abbott Vascular, Inc.

 

Evolve Short DAPT: A prospective, multicenter, single-arm study designed to assess the safety of 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing (PCI) with a SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System

Short Description: Coronary artery disease (CAD) is a narrowing of one or more blood vessels that supply blood and oxygen to the heart. Coronary stenting is a commonly used procedure to treat CAD. The coronary stenting procedure that will be performed and the SYNERGY stent is not investigational. To help prevent blood clots that could block the opening of the stent and lead to a heart attack, doctor's require subjects to take dual antiplatelet therapy (DAPT) which is aspirin and one the following medicines, such as Plavix, Effiant or Brilinta. The EVOLVE Short DAPT study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY Stent System.

Please contact Kate Dalton, MS, RD, CCRC at keb2114@columbia.edu if you have questions or would like to refer a patient.

Principal Investigator: Manish Parikh, MD

https://clinicaltrials.gov/ct2/show/NCT02605447?term=evolve+short+dapt&rank=1

Sponsor: Boston Scientific

 
 
 
 
 
 
 
 
 

 

 

bottom bar
top

Contact Us

Uptown

161 Ft. Washington Ave.
Herbert Irving Pavilion,
6th Floor
New York, NY 10032
212.305.7060

Midtown East

16 East 60th Street
New York, NY 10022
212.326.5745

Somers

CIVT–Westchester
Bailey Court
334 Route 100
Somers, NY 10589
914.277.4367
contact
bottom bar